Stephen M. Hahn - 12 Jun 2026 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Reporting relationship: Director
Issuer ticker: SNSE
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2026, 16:21:10 UTC
Source filing: View source filing
Reporting owner signature: /s/ Josiah Craver, Attorney-in-Fact

Key filing fact

Stephen M. Hahn filed Form 4 for Sensei Biotherapeutics, Inc. (SNSE) on 16 Jun 2026.

Key facts

This page summarizes Stephen M. Hahn's Form 4 filing for Sensei Biotherapeutics, Inc. (SNSE).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Jun 2026, 16:21.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002137706 Primary reporting owner

Hahn Stephen M.

Relationship: Director
Address: C/O FAETH THERAPEUTICS, INC., 701 TILLERY STREET #12 #1010, AUSTIN
Signature: /s/ Josiah Craver, Attorney-in-Fact
Signature date: 16 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNSE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +44,763
Change %
Price
Shares after: 44,763
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNSE transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +25,000
Change %
Price: $0.000000^*
Shares after: 25,000
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $13.00
Footnotes: F4

SNSE transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -45
Change %: -100%
Price
Shares after: 0
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,763
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date.

Footnote F2

Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger").

Footnote F3

Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock.

Footnote F4

The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.